Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$55.98 USD
-0.32 (-0.57%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $55.95 -0.03 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Price, Consensus and EPS Surprise
CYTK 55.98 -0.32(-0.57%)
Will CYTK be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CYTK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CYTK
Why Cytokinetics (CYTK) Stock Price Was Down 17% on Thursday
Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates
CYTK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Omega Therapeutics, Inc. (OMGA) Reports Q1 Loss, Tops Revenue Estimates
Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates
Should Vanguard S&P Small-Cap 600 ETF (VIOO) Be on Your Investing Radar?
Other News for CYTK
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Insider Sale at Cytokinetics Inc (CYTK): EVP Research & Development Fady Malik Sells Shares
7 Biotech Stocks to Boost Your Portfolio to Peak Health
Buy Rating Affirmed: Cytokinetics’ Aficamten Shows Strong Commercial Promise in oHCM Treatment
Cytokinetics price target lowered by $12 at JPMorgan, here's why